Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab + golimumab combination therapy versus monotherapy in moderately to severely active Crohn's disease
NL-OMON59606Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of guselkumab and golimumab in Crohn's disease (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Clinical remission and endoscopic response at Week 48. Started Mar 2023; status: active, not recruiting.
02
Drugs
guselkumabgolimumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON59606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59606.